ArticleBMC cancer2025
Clinicopathological characteristics and survival outcomes in early-stage endometrial clear cell carcinoma: a dual-center retrospective study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate clinicopathological predictors and evaluate the impact of adjuvant therapy on survival outcomes in patients with early-stage (FIGO 2023 Stage I-II) endometrial clear cell carcinoma (ECCC).
methodsThis dual-center retrospective study enrolled patients newly diagnosed with stage I-II ECCC between January 1, 2010 and December 31, 2023 at two tertiary hospitals in China. Clinicopathological parameters and survival outcomes were systematically analyzed. Kaplan-Meier curves and Cox regression analyses were used to assess the associations between variables and overall survival (OS) or progression-free survival (PFS).
resultsAmong 80 eligible patients (median age: 59 years), 30.0% (n = 24) were stage I and 70.0% (n = 56) stage II. After a median follow-up of 76 months, 11 patients experienced disease progression and 6 died, with 5-year PFS and OS rates of 87.0% and 91.6%, respectively. Kaplan-Meier survival analysis demonstrated no significant differences in PFS or OS between patients undergoing surgery alone versus surgery with adjuvant therapy. Multivariate Cox analysis identified positive peritoneal washing cytology (PWC) (HR = 8.062, 95% CI: 1.208–53.814, P = 0.031) and deep myometrial invasion (≥ 1/2) (HR = 7.455, 95% CI: 1.187–46.803, P = 0.032) as independent adverse prognostic factors for OS. Diabetes mellitus emerged as the only significant predictor for reduced PFS (HR = 3.831, 95% CI: 1.053–13.935, P = 0.042).
conclusionsPositive PWC and deep myometrial invasion (≥ 1/2) were independent adverse prognostic factors for OS in stage I-II ECCC, while diabetes mellitus emerged as the sole predictor of poorer PFS. Notably, adjuvant therapy failed to demonstrate any significant survival benefit compared to surgery alone in this cohort. These findings challenge the routine use of adjuvant therapy for stage I-II ECCC and underscore the importance of individualized risk stratification incorporating PWC, myometrial invasion depth and diabetic status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.